The Financial Impact of Introducing Darbepoetin Alfa (DA) as a New Long-Acting Erythropoiesis-Stimulating Agent Alternative for Non-Adherent Peritoneal Dialysis Patients in the Ministry of Health (MOH) Malaysia
Abstract
Authors
YV Yong